Gene mutation identified as cause of rare spastic ataxia

Researchers have discovered that mutations in the CD99L2 gene cause X-linked spastic ataxia, a rare movement disorder. The finding came from analysis of 2,811 patients with conditions affecting coordination and muscle control. The study was published in Nature Communications.

Scientists at Ruhr University Bochum and in Tübingen conducted genome-wide genetic analysis combined with cell experiments. They showed that CD99L2, previously known only for immune system functions, also supports communication between nerve cells by activating the CAPN1 protein.

"Disease-causing variants lead to disrupted production of the CD99L2 protein in the cell and prevent its interaction with CAPN1," said Dr. Jonasz Weber. Patients' cells displayed specific disruptions of synaptic processes, the researchers reported.

The work highlights the importance of pairing genetic diagnostics with functional studies. "Our results show that genetic diagnostics and functional neuroscience are not mutually exclusive areas," Weber added.

The discovery improves prospects for genetic diagnosis of rare movement disorders and provides new details on mechanisms of neurodegeneration.

Relaterte artikler

Photorealistic depiction of DHX29 protein selectively silencing inefficient mRNA codons in a human cell, illustrating new gene expression research.
Bilde generert av AI

Study identifies DHX29 as a key factor linking codon choice to selective silencing of inefficient genetic messages in human cells

Rapportert av AI Bilde generert av AI Faktasjekket

Researchers at Kyoto University and RIKEN report that human cells can detect “non-optimal” synonymous codons—alternative three-letter genetic instructions that encode the same amino acid but are translated less efficiently—and selectively suppress the corresponding mRNAs. In experiments described in Science, the team identifies the RNA-binding protein DHX29 as a central component of this codon-dependent control of gene expression.

Researchers at the Perelman School of Medicine at the University of Pennsylvania report that a protein called glycoprotein nonmetastatic melanoma B (GPNMB) may help drive the cell-to-cell spread of Parkinson’s-related alpha-synuclein pathology in lab models. In cultured-neuron experiments, antibodies designed to block GPNMB reduced the propagation of the toxic process, according to a study the team says was published in Neuron.

Rapportert av AI

A major analysis of genetic data has linked 127 gene locations to Alzheimer’s disease, including 48 previously unidentified ones. Researchers also flagged several genes as promising drug targets and highlighted changes in immune and nerve cells.

Dette nettstedet bruker informasjonskapsler

Vi bruker informasjonskapsler for analyse for å forbedre nettstedet vårt. Les vår personvernerklæring for mer informasjon.
Avvis